WHO Urges Faster Action Against Tuberculosis (TB)

The World Health Organization (WHO) is calling for a significant acceleration in the detection and treatment of tuberculosis (TB), a disease that remains one of the world’s leading infectious killers. New guidance released this week focuses on expanding access to faster, more accurate diagnostic tools, a move officials say could be “truly transformative” in the fight against the disease.

Faster Diagnosis: A Game Changer?

TB is caused by bacteria that primarily affect the lungs, spreading through the air when an infected person coughs, sneezes, or spits. Even as preventable and curable with antibiotics, TB continues to claim over 1.2 million lives annually, according to the WHO’s latest data from 2024. The disease is particularly devastating in Southeast Asia, accounting for nearly 40% of global deaths. The new WHO guidelines emphasize the deployment of innovative diagnostic tests, including near-point-of-care molecular tests and, crucially, tongue swabs.

These new tests represent a significant leap forward. They cost roughly half the price of current diagnostic methods, operate on battery power – making them suitable for resource-limited settings – and deliver results in under an hour. This speed is critical, as earlier diagnosis translates directly to earlier treatment and a reduced risk of transmission. For the first time, tongue swabs allow testing for individuals, including young people, who are unable to produce sputum (phlegm), a traditional requirement for TB diagnosis. This expands testing access to those at higher risk of dying from the disease.

Who is Most Affected?

Globally, an estimated 10.7 million people fell ill with TB in 2024, with a roughly even split between men and women, and approximately 1.2 million cases occurring in children. TB is present in every country, but the burden is heavily concentrated in a handful of nations. India accounts for 26% of global cases, followed by Indonesia (10%), China (6.8%), the Philippines (6.8%), and Pakistan (6.3%). The Americas are also seeing a resurgence, with cases increasing by 6.6% in 2023, although deaths have begun to decline, potentially linked to improved diagnosis and treatment rates. The Pan American Health Organization (PAHO) reports that 78% of people diagnosed with TB in the Americas are now receiving treatment, up from 76% in 2022.

Beyond Speed: Expanding Diagnostic Capabilities

The benefits of these new diagnostic tools extend beyond TB itself. The WHO notes that the technology has the potential to test for other diseases, including HIV, mpox, and HPV. This multi-disease capability could significantly strengthen public health infrastructure, particularly in regions with limited resources. The guidelines recommend a sputum pooling strategy, where samples from multiple individuals are tested together. This approach can improve testing efficiency and reduce costs, especially when resources are constrained.

Understanding Drug-Resistant TB

A particularly concerning aspect of the TB epidemic is the rise of multidrug-resistant TB (MDR-TB). According to the WHO, only about 2 in 5 people with drug-resistant TB accessed treatment in 2024. MDR-TB requires longer, more complex, and more expensive treatment regimens, and poses a significant threat to global health security. Faster and more accurate diagnosis is crucial for identifying and treating drug-resistant strains effectively.

The Importance of Context: TB and Underlying Health Conditions

While TB is an infectious disease, certain underlying health conditions can significantly increase a person’s risk of developing active TB disease. These include diabetes, weakened immune systems (such as those seen in people with HIV), undernutrition, tobacco use, and harmful alcohol consumption. The WHO highlights that TB was both the leading killer of people with HIV in 2024 and a major contributor to deaths related to antimicrobial resistance. The WHO fact sheet on tuberculosis provides a comprehensive overview of these risk factors and the interplay between TB and other health challenges.

What Does This Imply for Individuals?

The WHO’s guidance is directed at national health systems, not individuals. It does *not* change recommendations for personal preventative measures. If you suspect you may have TB – experiencing symptoms like a persistent cough, fever, night sweats, or weight loss – it is crucial to consult a qualified healthcare professional for evaluation and testing. Early diagnosis and treatment are the most effective ways to prevent the spread of the disease and ensure a positive outcome.

Public Health Surveillance and Future Directions

The WHO’s call for expanded diagnostic access is part of a broader effort to end TB globally. This includes strengthening surveillance systems to track the spread of the disease, investing in research and development of new diagnostics and treatments, and addressing the social and economic factors that contribute to TB transmission. The organization is also working to improve access to preventative therapy for people at high risk of developing TB disease. The UN News report on the WHO guidance emphasizes that these new tools could be “truly transformative” by bringing faster, accurate diagnosis closer to people in need.

Looking ahead, the WHO will continue to monitor the impact of these new diagnostic tools and update its guidance as new evidence emerges. Ongoing research is focused on developing even more rapid and accurate diagnostics, as well as new treatment regimens that are shorter, more effective, and less toxic. The ultimate goal is to eliminate TB as a public health threat, but achieving this will require sustained commitment and investment from governments, international organizations, and the global health community.